AAVantgarde Bio to Present USH1B Trial Progress

The biotech company will share clinical updates on its Usher syndrome type 1B gene therapy at two December 2026 scientific meetings.

Updated on Nov. 12, 2026 in Biotech

Clear unlabeled glass vials of pale amber liquid lined up on a steel laboratory bench, with a soft blurred lab wall behind them.
AAVantgarde Bio will present clinical progress on its Usher syndrome type 1B gene therapy at EYENOVATE on December 3 and at FLORetina-ICOOR on December 4, 2026. AI Illustration. Upload story photo >

AAVantgarde Bio, a clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases, announced upcoming presentations on clinical progress for its Usher syndrome type 1B program. The company will present at the EYENOVATE and FLORetina-ICOOR 2026 meetings, with the EYENOVATE presentation scheduled for 3 December 2026.

Why it matters

Stargardt disease and Usher syndrome type 1B are severe inherited retinal diseases with no approved treatments, so updates on dual-AAV gene therapy programs are closely watched by patients, clinicians and investors. The presentations offer a scheduled opportunity for the company to share clinical data and discuss partnering.

The LUCE-1 Phase I/II trial (NCT06591793) evaluates a dual-AAV MYO7A gene therapy using AAVantgarde's proprietary dual-AAV platform. The announcement did not include specific vector dosing, efficacy endpoints or patient numbers, leaving the technical performance of the therapy undisclosed.

The players

AAVantgarde Bio

AAVantgarde Bio is a clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases using proprietary dual-AAV technologies.

Natalia Misciattelli

Natalia Misciattelli is the chief executive officer of AAVantgarde Bio and leads the company's development of gene therapies for inherited retinal disease.

The details

AAVantgarde Bio announced it will present clinical progress on its USH1B program at the EYENOVATE presentations on 3 December 2026 and at the FLORetina-ICOOR presentation on 4 December 2026. The LUCE-1 trial is a Phase I/II study of a dual-AAV MYO7A gene therapy for retinitis pigmentosa associated with Usher syndrome type 1B, and the company said it is available for partnering and scientific discussions during the congress.

Timeline

  1. 3 December 2026: EYENOVATE presentations on LUCE-1 trial and Stargardt/Usher 1B therapies

  2. 3-6 December 2026: FLORetina-ICOOR 2026 Meeting in Florence, Italy

  3. 4 December 2026: FLORetina-ICOOR presentation on MYO7A gene therapy

Roadmap

AAVantgarde Bio's presentations build on its LUCE-1 trial, a dual-AAV gene therapy study targeting MYO7A-associated retinitis pigmentosa. The company's programs in Stargardt disease and Usher syndrome type 1B reflect a broader effort to bring gene therapies to inherited retinal diseases that currently lack approved treatments.

For people living with Usher syndrome type 1B or Stargardt disease, the presentations signal ongoing clinical development of gene therapies for conditions that currently have no approved treatment. Readers seeking to follow the research can track the scheduled congress presentations for updated trial information.

The takeaway

Gene therapy programs for inherited retinal diseases are advancing into clinical stages, and scheduled congress presentations are a useful checkpoint for tracking trial progress. Readers interested in these conditions can follow updates from the December 2026 meetings.

What happens next

AAVantgarde Bio is scheduled to present clinical progress on its USH1B program at EYENOVATE on 3 December 2026 and at FLORetina-ICOOR on 4 December 2026.

Further reading

For more on related therapies, explore recent coverage in Biotech.

Source note: This article includes information reported by The Manila times.